
AstraZeneca Abandons Neuroscience, Prioritizes Weight Loss, Immunology
AstraZeneca will no longer play in the neuroscience space, company executives said in an investor call on Tuesday, presenting the pharma’s first-quarter 2025 earnings report. “There’s a lot of things we can’t fund and we cannot be everywhere,” CEO Pascal …